JPS5824520A - 精神病治療薬 - Google Patents
精神病治療薬Info
- Publication number
- JPS5824520A JPS5824520A JP57125224A JP12522482A JPS5824520A JP S5824520 A JPS5824520 A JP S5824520A JP 57125224 A JP57125224 A JP 57125224A JP 12522482 A JP12522482 A JP 12522482A JP S5824520 A JPS5824520 A JP S5824520A
- Authority
- JP
- Japan
- Prior art keywords
- trans
- acid
- side effects
- treatment
- psychosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims description 3
- 239000003814 drug Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 5
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 abstract description 4
- 201000000980 schizophrenia Diseases 0.000 abstract description 4
- 229960004558 terguride Drugs 0.000 abstract description 4
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000009132 Catalepsy Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000030663 Libido disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydrogen salt Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940096717 pamine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813129714 DE3129714A1 (de) | 1981-07-23 | 1981-07-23 | Anti-psychotikum |
| DE3129714.5 | 1981-07-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5824520A true JPS5824520A (ja) | 1983-02-14 |
| JPH0352446B2 JPH0352446B2 (enExample) | 1991-08-12 |
Family
ID=6137904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57125224A Granted JPS5824520A (ja) | 1981-07-23 | 1982-07-20 | 精神病治療薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4522820A (enExample) |
| EP (1) | EP0071563B1 (enExample) |
| JP (1) | JPS5824520A (enExample) |
| AT (1) | ATE22010T1 (enExample) |
| DE (2) | DE3129714A1 (enExample) |
| IE (1) | IE54257B1 (enExample) |
| ZA (1) | ZA825314B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2112382B (en) * | 1981-11-06 | 1985-03-06 | Erba Farmitalia | Ergoline derivatives |
| DE3410218A1 (de) * | 1984-03-16 | 1985-09-19 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Tergurid als antihypertensivum |
| EP0208417A3 (en) * | 1985-06-12 | 1989-09-06 | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu | Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis |
| EP2083008A1 (en) * | 2007-12-07 | 2009-07-29 | Axxonis Pharma AG | Ergoline derivatives as selective radical scavengers for neurons |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH573936A5 (enExample) * | 1971-08-05 | 1976-03-31 | Spofa Vereinigte Pharma Werke | |
| DE2359128A1 (de) * | 1973-11-24 | 1975-06-12 | Schering Ag | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen |
-
1981
- 1981-07-23 DE DE19813129714 patent/DE3129714A1/de not_active Withdrawn
-
1982
- 1982-07-02 DE DE8282730092T patent/DE3273177D1/de not_active Expired
- 1982-07-02 AT AT82730092T patent/ATE22010T1/de not_active IP Right Cessation
- 1982-07-02 EP EP82730092A patent/EP0071563B1/en not_active Expired
- 1982-07-20 JP JP57125224A patent/JPS5824520A/ja active Granted
- 1982-07-22 IE IE1752/82A patent/IE54257B1/en not_active IP Right Cessation
- 1982-07-23 US US06/401,427 patent/US4522820A/en not_active Expired - Lifetime
- 1982-07-23 ZA ZA825314A patent/ZA825314B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3273177D1 (en) | 1986-10-16 |
| EP0071563B1 (en) | 1986-09-10 |
| IE821752L (en) | 1983-01-23 |
| ATE22010T1 (de) | 1986-09-15 |
| JPH0352446B2 (enExample) | 1991-08-12 |
| EP0071563A1 (en) | 1983-02-09 |
| US4522820A (en) | 1985-06-11 |
| IE54257B1 (en) | 1989-08-02 |
| ZA825314B (en) | 1983-05-25 |
| DE3129714A1 (de) | 1983-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3876877T2 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| DE69904922T2 (de) | Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält | |
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| EP1648432A1 (de) | Verwendung von rotigotin zur behandlung von depressionen | |
| MX2015003812A (es) | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. | |
| EA014189B1 (ru) | Применение флибансерина для лечения расстройств полового влечения в предклимактерический период | |
| US20220023316A1 (en) | Methods for the treatment of depression | |
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP7429942B2 (ja) | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 | |
| TWI250872B (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| JP2023506480A (ja) | アルツハイマー病の治療のための化合物 | |
| JPS5824520A (ja) | 精神病治療薬 | |
| JP2011121975A (ja) | 線維筋痛症に伴う疼痛を改善するための線維筋痛症に伴う疼痛改善用医薬組成物 | |
| EP1461042B1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| DE60203106T2 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
| AU2016364670A1 (en) | Methods of treating or alleviating mental disorders and associated symptoms | |
| ITMI951417A1 (it) | Composizioni farmaceutiche e procedimento per la loro preparazione | |
| KR20200121819A (ko) | 하지 불안 증후군을 치료하기 위한 치료제 | |
| JPWO2006006617A1 (ja) | 中枢神経疾患発症後の機能障害の回復促進剤 | |
| EP4146214A1 (en) | Use of dopamine d3 partial agonists for treating central nervous system disorders | |
| DE10318714B4 (de) | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches | |
| EP4523686A1 (en) | A sigma-1 receptor positive modulator for its use in the prevention and the treatment of a pathology | |
| CA3076180C (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| JP6216913B1 (ja) | 医薬組成物 |